Trial
NCT04561817
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
—
Condition
Ovarian Neoplasms
Intervention
Ipatasertib
Why stopped
Evolving data with Ipatasertib that changes the known risk / benefit background in pursuing future studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-06